Core Viewpoint - The company Shuyou Shen (300204) anticipates a significant net loss for the fiscal year 2025, with projected losses ranging from 69.81 million to 85.33 million yuan, indicating a challenging financial outlook due to external factors and industry policies [1] Financial Performance - The expected net profit, excluding non-recurring gains and losses, is projected to be between 74.09 million and 90.56 million yuan [1] - The anticipated operating revenue is estimated to be between 198 million and 242 million yuan, a decrease from the previous year's revenue of 325 million yuan [1] - After adjustments, the operating revenue is also expected to fall within the same range of 198 million to 242 million yuan [1] Business Operations - The company reports that its production and operational activities are normal, with slight growth in sales revenue and volume for its product Su Tai [1] - However, the revenue from the product Shuyou Qing has declined due to external environmental factors and industry policies [1] Market Expansion - The company is actively working to expand its market for polyethylene glycol series products [1] - The expected non-recurring gains and losses for the fiscal year 2025 are approximately 4.75 million yuan [1]

证券日报网讯 1月28日，舒泰神发布公告称，公司预计2025年度营业收入19，830.77万元至24，237.61 万元，上年同期为32，481.60万元；归属于上市公司股东的净利润为-8，532.76万元至-6，981.35万元， 上年同期亏损14，484.26万元。 （文章来源：证券日报） ...

Core Viewpoint - Shuyou Shen (300204) forecasts a net profit attributable to shareholders for 2025 to be between -69.81 million and -85.33 million yuan, indicating a potential loss for the year [1] Group 1: Financial Performance - The company anticipates a net profit loss for 2025, with estimates ranging from -69.81 million to -85.33 million yuan [1] - Despite the projected losses, the company reports slight growth in sales revenue and volume for its product Su Tai [1] Group 2: Market and Product Development - The company is actively engaged in marketing and market exploration activities during the reporting period [1] - Revenue from the product Shuyou Qing has declined due to external environmental factors and industry policies [1] - The company is exploring multiple channels to expand the market for Shuyou Qing products and is focusing on marketing efforts for polyethylene glycol series products [1]

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, with a net profit excluding non-recurring gains and losses estimated between -90.56 million and -74.09 million yuan, and operating revenue projected to be between 198.31 million and 242.38 million yuan [1] Group 1 - During the reporting period, the company's production and operational activities were normal, and it actively engaged in various marketing and market exploration efforts, resulting in slight growth in sales revenue and volume of the product Su Tai [1] - The revenue from the product Shutaqing decreased due to external environment and industry policy factors; the company is exploring multiple channels for the Shutaqing product market and focusing on expanding the marketing efforts for polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shusitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shuyi Qing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shuchang Qing)" [1] - The company expects non-recurring gains and losses for the year 2025 to be approximately 4.75 million yuan, with specific data to be disclosed in the 2025 annual report [1]

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, indicating a challenging financial outlook for the upcoming year [1] Financial Performance - The company anticipates a net profit excluding non-recurring gains and losses to range from -90.56 million to -74.09 million yuan for 2025 [1] - Projected operating revenue for the same period is estimated to be between 198.31 million and 242.38 million yuan [1] Business Operations - During the reporting period, the company's production and operational activities were normal, with a slight increase in sales revenue and volume for the product Su Tai [1] - The revenue from the product Shutaqing has decreased due to external environmental factors and industry policies, prompting the company to explore multiple channels for market expansion [1] Product Development - The company is focusing on marketing efforts for its polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shu Sitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shu Yiqing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shu Changqing)" [1] Non-recurring Gains and Losses - The company expects non-recurring gains and losses for 2025 to be approximately 4.75 million yuan, with specific figures to be disclosed in the annual report [1]

Financial Projections - The company expects a net profit of approximately -85.33 million CNY for the year 2025, compared to -69.81 million CNY in the same period last year[4]. - Revenue for the year 2025 is projected to be around 198.31 million CNY, down from 242.38 million CNY in the previous year, representing a decrease of approximately 18.2%[4]. - The net profit after deducting non-recurring gains and losses is expected to be -90.56 million CNY, compared to -74.09 million CNY in the previous year[4]. - The expected non-recurring gains and losses for 2025 are approximately 4.75 million CNY, with specific data to be disclosed in the annual report[7]. - The financial data presented is preliminary and has not been audited by the accounting firm[5]. - The detailed financial results for 2025 will be disclosed in the company's annual report, urging investors to make cautious decisions[8]. Sales Performance - The company reported a slight increase in sales revenue and volume for its product Su Tai Shen during the reporting period[6]. - Revenue from the product Shu Tai Qing has declined due to external environment and industry policy factors, prompting the company to explore multiple channels for market expansion[7]. Marketing Strategy - The company is focusing on marketing efforts for its new polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shu Si Tong)" and "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shu Yi Qing)"[7].

数据显示，中信保诚基金旗下1只基金重仓舒泰神。中信保诚至瑞混合A（003432）四季度增持6万股， 持有股数35.5万股，占基金净值比例为4%，位居第六大重仓股。根据测算，今日浮亏损失约51.83万 元。 中信保诚至瑞混合A（003432）成立日期2016年10月21日，最新规模1.34亿。今年以来收益1.83%，同 类排名6888/8861；近一年收益7.03%，同类排名6921/8126；成立以来收益72.96%。 中信保诚至瑞混合A（003432）基金经理为王睿、朱慧灵。 1月27日，舒泰神跌5.2%，截至发稿，报26.60元/股，成交3.83亿元，换手率3.13%，总市值127.09亿 元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 朱慧灵累计任职时间301天，现任基金资产总规模2.42亿元 ...

Group 1 - The chemical pharmaceutical sector increased by 0.91% on January 23, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Guangshantang's stock price rose by 20.00% to 96.28, with a trading volume of 185,500 shares [1] Group 2 - The main funds in the chemical pharmaceutical sector experienced a net outflow of 487 million yuan, while retail investors saw a net inflow of 1.12 billion yuan [2] - The stock performance of several companies showed varied results, with some experiencing declines, such as Xingqi Eye Medicine down 4.86% [2] - The trading volume and turnover for various companies in the sector were significant, with notable figures such as 1.62 billion yuan for Xingqi Eye Medicine [2] Group 3 - Guangshantang had a net inflow of 396 million yuan from main funds, while retail investors had a net outflow of 136 million yuan [3] - Other companies like Hancheng Group and Shutaishen also showed significant net inflows and outflows, indicating varied investor sentiment [3] - The data reflects a mixed investment environment within the chemical pharmaceutical sector, with both institutional and retail investors actively participating [3]

A股市场 创新药概念股走强，其中， 广生堂20CM涨停， 华兰股份涨12%， 汉商集团10CM涨停， 海特 生物涨超7%， 必贝特涨超6%， 舒泰神、 成都先导、 海王生物涨超5%， 九州通、 泓博医药、 华纳药 厂涨超4%。 ...

Group 1 - The core viewpoint of the news is that the A-share market is seeing a strong performance in innovative drug concept stocks, driven by a policy encouraging the sale of innovative drugs and reference preparations in retail pharmacies [1] Group 2 - Guangshentang (300436) experienced a 20% increase, with a total market value of 15.3 billion and a year-to-date increase of 8% [2] - Zhongsan Co. (301093) rose by 12%, with a market capitalization of 13.8 billion and a year-to-date increase of 63.89% [2] - Hanshang Group (600774) saw a 10% increase, with a market value of 3.408 billion and a year-to-date increase of 26.37% [2] - Hite Bio (300683) increased by 7.92%, with a market capitalization of 4.371 billion and a year-to-date increase of 20.41% [2] - Bibete (688759) rose by 6.64%, with a market value of 24.9 billion and a year-to-date increase of 90.09% [2] - Shutaishen (300204) increased by 5.78%, with a market capitalization of 13.6 billion and a year-to-date increase of 4.58% [2] - Chengdu Xian Dao (688222) rose by 5.42%, with a market value of 13.8 billion and a year-to-date increase of 46.78% [2] - Haiwang Bio (000078) increased by 5.23%, with a market capitalization of 10.1 billion and a year-to-date increase of 10.40% [2] - Jiuzhoutong (600998) rose by 4.71%, with a market value of 28 billion and a year-to-date increase of 8.59% [2] - Hongbo Pharmaceutical (301230) increased by 4.60%, with a market capitalization of 6.76 billion and a year-to-date increase of 62.48% [2] - Huana Pharmaceutical (688799) rose by 4.09%, with a market value of 6.882 billion and a year-to-date increase of 9.87% [2]